Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
CD70 VHH - 01 | Lead | Hematological Malignancy | Non-hodgkin lymphoma |
Immobilized Anti-CD27 Ligand Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) with a linear range of 0.039-0.156 μg/mL (QC tested).
The purity of FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) is more than 85% and the molecular weight of this protein is around 55-74 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Myelodysplastic Syndromes; Neoplasms; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
PRO-1160 | PRO-1160 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Solid tumours; Urologic Neoplasms; Lymphoma | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
SEA-CD70 | SEA-CD70 | Phase 1 Clinical | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
BR-108 | BR-108 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Leukemia; Hematologic Neoplasms | Details |
ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Neoplasms | Details | |
Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, T-Cell | Details | |
CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Hematologic Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Myeloid, Acute | Details | |
CD70-CART(Hrain) | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Neoplasms; Genital Neoplasms, Female; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details | |
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics Ag | Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa | Carcinoma, Renal Cell | Details |
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) | Tongji University | Details | |||
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Myelodysplastic Syndromes; Neoplasms; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
PRO-1160 | PRO-1160 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Solid tumours; Urologic Neoplasms; Lymphoma | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
SEA-CD70 | SEA-CD70 | Phase 1 Clinical | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
BR-108 | BR-108 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Leukemia; Hematologic Neoplasms | Details |
ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Neoplasms | Details | |
Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, T-Cell | Details | |
CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Hematologic Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Myeloid, Acute | Details | |
CD70-CART(Hrain) | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Neoplasms; Genital Neoplasms, Female; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details | |
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics Ag | Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa | Carcinoma, Renal Cell | Details |
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) | Tongji University | Details |
This web search service is supported by Google Inc.